Cargando…
1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study)
BACKGROUND: Baloxavir marboxil (BXM), a selective cap-dependent endonuclease inhibitor, has demonstrated efficacy + safety for influenza in otherwise healthy patients. We present subgroup analyses for (i) United States vs. Japan (J), (ii) time (t) of treatment (early: ≥0 to ≤24 hours, vs. late: >...
Autores principales: | Kawaguchi, Keiko, Portsmouth, Simon, Shishido, Takao, Uehara, Takeki, Hayden, Frederick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252458/ http://dx.doi.org/10.1093/ofid/ofy209.115 |
Ejemplares similares
-
LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018) -
Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
por: Portsmouth, Simon, et al.
Publicado: (2020) -
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020) -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018) -
Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)